Recombinant DNA Technology Market Performance and Future Outlook at 9.2% CAGR Through 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the recombinant dna technology market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Size Of The Recombinant DNA Technology Industry By 2029?

The recombinant dna technology market size has seen significant expansion in recent years. It is anticipated to increase from $858.94 billion in 2024 to $913.42 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. The growth observed in the historical period stems from elements such as healthcare demands, the development of the biopharmaceutical industry, increased investments in research and development, and the rise of personalized medicine.

The recombinant dna technology market size is set for significant growth in the coming years. By 2029, it is projected to expand to $1299.96 billion, with a compound annual growth rate (CAGR) of 9.2%. This expansion during the forecast period stems from factors such as an increase in chronic illnesses, the emergence of new biotech startups, augmented funding in biotech, the globalization of biotech markets, and increased consumer acceptance and knowledge. Prominent trends for this period include scientific breakthroughs, advancements in gene editing, the development of cell and gene therapies, the evolution of RNA therapeutics, their therapeutic uses in rare diseases, and the integration of AI and data.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp

What Major Drivers Are Impacting The Recombinant DNA Technology Market?

The growing prevalence of chronic diseases is projected to boost the recombinant DNA technology market’s expansion. These conditions are defined as ailments lasting a year or more, demanding continuous medical care, limiting daily activities, or both. Recombinant DNA technology has enhanced healthcare through the development of biopharmaceutical proteins for drug applications and by replacing faulty genes with healthy ones via gene therapy, aiming to cure illnesses. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that by 2050, over 35 million new cancer cases were projected, indicating a 77% increase from the estimated 20 million cases in 2022. Hence, the rise in chronic diseases is propelling the growth of the recombinant DNA technology market.

Which Segment Categories Are Driving Maximum Growth In The Recombinant DNA Technology Market?

The recombinant dna technologymarket covered in this report is segmented –

1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing

2) By Component Type: Expression System, Cloning Vector

3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types

4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types

Subsegments:

1) By Recombinant Protein Drugs: Hormones, Growth Factors

2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines

3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop

4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems

5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies

6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)

Which Long-Term Trends Will Play A Crucial Role In The Recombinant DNA Technology Market?

Technological advancement represents a principal trend in the recombinant DNA technology market. Major companies operating in the recombinant DNA technology market are prioritizing innovative technologies to sustain their market position. For instance, in August 2022, Bluebird bio, Inc., a US-based biotechnology company, launched ZYNTEGLO, which received approval from the U.S. Food and Drug Administration (FDA). This is a one-time gene therapy that addresses beta-thalassemia by targeting its genetic cause, providing patients with the opportunity to become independent of regular red blood cell transfusions. It employs an ex-vivo lentiviral vector to modify patient cells and is the first FDA-approved gene therapy for this condition in the U.S. This breakthrough mitigates the lifelong burden of managing beta-thalassemia.

Who Are The Dominant Players In The Recombinant DNA Technology Market Today?

Major companies operating in the recombinant DNA technology market are Profacgen BioTech Corp., Amgen Inc., Novartis International AG, GenScript Biotech Corporation, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co. Inc., Biogen Inc., GlaxoSmithKline PLC, New England Biolabs Inc., Bayer CropScience, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Moderna Inc., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc., bluebird bio Inc., Illumina Inc., Qiagen N.V., Lonza Group AG, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Becton Dickinson and Company, Sartorius AG, Abcam PLC, Horizon Discovery Group PLC, Integrated DNA Technologies Inc., Twist Bioscience Corporation, Synthego Corporation, Codex DNA Inc., InvivoGen, Eurofins Scientific SE, Sarepta Therapeutics Inc., Sangamo Therapeutics Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report

Which Region Is At The Forefront Of Innovation In The Recombinant DNA Technology Market?

North America was the largest region in the recombinant DNA technology market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant DNA technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=8233&type=smp

Browse Through More Reports Similar to the Global Recombinant DNA Technology Market 2025, By The Business Research Company

Cells Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Cell Culture Consumables And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Cell Based Assays Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795